Pharmacore secures funding to improve medication regimen reviews in long-term care Verizon Frontline deployed in support of National Guard training exercise
MUSCATATUCK, Ind., June 12, 2023 (GLOBE NEWSWIRE) — The Verizon Frontline Crisis Response Team on…
Over 75% of HR Leaders Will Use AI in the Next Year, According to New Paychex Research
Over three-fourths of HR leaders in companies with 20 or more employees say they’ll use…
TOYOTA GAZOO Racing second in Le Mans thriller
TOKYO, Jun 12, 2023 – (JCN Newswire) – TOYOTA GAZOO Racing?s winning streak at the…
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE
HONG KONG, Jun 12, 2023 – (ACN Newswire) – A Hong Kong-based biopharmaceutical company dedicated…
Doubleview Gold Corp. Provides Drilling Update on Hat Project Exploration
Vancouver, BC, Jun 12, 2023 – (ACN Newswire) – Doubleview Gold Corp. (TSXV: DBG) (OTCQB:…
Capstone Green Energy Secures Follow-on Order for Two Microturbines for Use at Canadian Oil and Gas Site
Third Order From Customer Within a Year, Customer Cites Cost Savings and Emissions Reductions as…
Spearmint Energy Secures $200 Million Term Loan for BESS Storage Portfolio Development
Supports the Development of Spearmint’s 1.2 GW / 2.4 GWh BESS Portfolio in ERCOT Power…
BlackSky Secures More Than $30 Million Contract for High-Frequency Imagery Services with International Defense Sector Customer
Multi-year renewed commitment expands assured subscription-based access to high-frequency, dawn-to-dusk imagery and AI-driven analytics HERNDON,…
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
LP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s…
The Top Ten Jobs To Be Replaced By AI In Next 5 Years – According to ChatGPT Research!
1. Coders and Software Developers: AI’s speed and accuracy have the potential to automate coding…
Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
Lugano, Switzerland, June, 12, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company…
Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
Lugano, Switzerland, June, 12, 2023 – Helsinn Group (“Helsinn”), a fully integrated global biopharma company…
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
– Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE…
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
– Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE…
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
The Company expands technology for patients with obsessive-compulsive disorder MALVERN, Pa., June 12, 2023 (GLOBE…
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
The Company expands technology for patients with obsessive-compulsive disorder MALVERN, Pa., June 12, 2023 (GLOBE…
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site…
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site…
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
Webcast scheduled for Thursday, June 15 at 8:30am PT IRVINE, Calif., June 12, 2023 (GLOBE…
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
Webcast scheduled for Thursday, June 15 at 8:30am PT IRVINE, Calif., June 12, 2023 (GLOBE…